155 related articles for article (PubMed ID: 36524618)
1. Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status.
Zhang J; Mao J; Xu D; Jiang S; Guo T; Zhou Y; Chu L; Yang X; Chu X; Ni J; Zhu Z
Cancer Med; 2023 Mar; 12(6):6971-6979. PubMed ID: 36524618
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
3. Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Wang Y; Li Y; Xia L; Niu K; Chen X; Lu D; Kong R; Chen Z; Sun J
Clin Transl Oncol; 2018 Mar; 20(3):366-373. PubMed ID: 28776311
[TBL] [Abstract][Full Text] [Related]
4. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
5. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
Liu Y; Zhang Z; Rinsurongkawong W; Gay CM; Le X; Ning MS; Lewis J; Rinsurongkawong V; Lee JJ; Roth J; Swisher S; Gandhi S; Lee PP; Gibbons DL; Vaporciyan AA; Heymach JV; Zhang J; Lin SH
JAMA Netw Open; 2022 Jun; 5(6):e2215589. PubMed ID: 35666500
[TBL] [Abstract][Full Text] [Related]
6. Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K; Semba H
Cancer Treat Res Commun; 2020; 22():100163. PubMed ID: 31675534
[TBL] [Abstract][Full Text] [Related]
7. EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Kim H; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
Cancer Res Treat; 2023 Apr; 55(2):498-505. PubMed ID: 36228655
[TBL] [Abstract][Full Text] [Related]
8. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Miyawaki T; Kenmotsu H; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
BMC Cancer; 2021 Nov; 21(1):1247. PubMed ID: 34798865
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
10. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
[TBL] [Abstract][Full Text] [Related]
11. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
12. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
15. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
17. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands.
Ten Berge DMHJ; Damhuis RAM; Aerts JGJV; Dingemans AC
Lung Cancer; 2023 Jul; 181():107253. PubMed ID: 37236088
[TBL] [Abstract][Full Text] [Related]
20. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Aredo JV; Wakelee HA; Hui AB; Padda SK; Joshi ND; Guo HH; Chaudhuri A; Diehn M; Loo BW; Neal JW
Cancer Treat Res Commun; 2022; 33():100659. PubMed ID: 36427429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
